PCSK9 and Hypercholesterolemia: Schulman et al. estimate that in a typical insurance pool, if 5 % of the estimated 27 % of US adults 40–64 years of age who have hypercholesterolaemia were eligible for a PCSK9 inhibitor, annual premiums would increase by approximately $124 per person; taxpayers would face the burden of similar increases in the cost of the Medicare Part D program [83].